Preoperative markers for the prediction of high-risk features in endometrial cancer

Table 3 Associations between cancer antigen 125 and human epididymis protein 4 and various pathological characteristics

Pathological characteristics		No. of cases	CA125 (U/mL)		HE4 (pmol/L)
			Median	Min-Max	Median	Min-Max
Tumor size	≤ 2 cm	38	16.1	6.9-556.4	68.9	30.5-649.1
	> 2 cm	90	23.8	5.3-786.8	128.3	35.0-1719.0
			P = 0.03		P < 0.001
Tumor grade	1 + 2	93	22.1	5.3-786.8	98.8	30.5-1132.0
	3	35	20.6	7.1-556.4	117.7	43.6-1719.0
			P = 0.71		P = 0.78
Myometrial invasion	≤ 50%	69	19.1	5.3-786.8	83.0	30.5-860.2
	> 50%	59	27.5	7.1-479.5	130.6	39.4-1719.0
			P = 0.01		P = 0.006
Lymphovascular space invasion	No	95	19.4	5.3-786.8	88.3	30.5-1132.0
	Yes	33	55.8	11.7-479.5	165.7	39.4-1719.0
			P < 0.001		P = 0.003
Cervical involvement	No	102	21.3	5.3-786.8	94.3	30.5-860.2
	Yes	26	25.0	10.0-479.5	300.0	39.4-1719.0
			P = 0.15		P = 0.05
Extrauterine metastasis	No	91	19.1	5.3-556.4	87.0	30.5-585.3
	Yes	37	54.6	10.0-786.8	183.5	39.4-1719.0
			P < 0.001		P < 0.001
Node metastasis	Negative	106	19.3	5.3-786.8	93.0	30.5-1132.0
	Positive	13	57.0	11.7-439.2	128.6	39.4-1719.0
			P = 0.004		P = 0.15
Any high-risk features	No	55	16.3	5.3-432.1	81.7	30.5-293.9
	Yes	73	27.5	7.1-786.8	130.5	39.4-1719.0
			P < 0.001		P < 0.001
Stage of disease	Early	101	19.3	5.3-786.8	89.5	30.5-1132.0
	Advanced	27	57.0	9.5-479.5	283.0	39.40 - 1719.0
			P < 0.001		P < 0.001

CA125: Cancer antigen 125; HE4: Human epididymis protein 4.